Avior Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Avior Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30	Closed	-$1.97K	–	929
2024 Q4	$1.97K	Hold	30	–	–	﹤0.01%	2119
2024 Q3	$2.11K	Hold	30	–	–	﹤0.01%	1968
2024 Q2	$2.47K	Sell	30 -341	-92%	-$28.4K	﹤0.01%	1902
2024 Q1	$32.4K	Buy	+371	New	+$33.2K	﹤0.01%	1403
2020 Q1	–	Sell	-49	Closed	-$4K	–	775
2019 Q4	$4K	Buy	49 +40	+444%	+$3.02K	﹤0.01%	661
2019 Q3	$0	Buy	+9	New	+$693	﹤0.01%	783
2019 Q1	–	Sell	-1,081	Closed	-$92K	–	651
2018 Q4	$92K	Hold	1,081	–	–	0.02%	438
2018 Q3	$105K	Hold	1,081	–	–	0.02%	432
2018 Q2	$102K	Sell	1,081 -13	-1%	-$1.14K	0.02%	439
2018 Q1	$89K	Sell	1,094 -74	-6%	-$6.35K	0.02%	449
2017 Q4	$104K	Buy	+1,168	New	+$102K	0.02%	442

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avior Wealth Management's BMRN Position: Q1 2025 in Review

Avior Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 30 shares — an estimated $1.97K sold.

Avior Wealth Management first reported a position in BMRN in Q4 2017 and held it in 11 quarters. The position peaked at $105K in Q3 2018. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Avior Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Avior Wealth Management sold 30 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $1.97K.
Avior Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 11 quarters.
Avior Wealth Management's BioMarin Pharmaceuticals position peaked at $105K in Q3 2018.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.